Ian Spatz’s commentary and research on health policy and pharmaceutical issues have appeared in Health Affairs, The New York Times, STAT, and peer-reviewed journals
Selected Publications
Spatz, I. (2025). Most Favored Nation Drug Pricing: Aiming at Pharma’s Achilles Heel. Health Affairs Forefront.
Spatz, I. (2022). Implementing The Drug Negotiation Provisions of the IRA: Considerations For CMS. Health Affairs Forefront.
Van Nuys, K., Goldman, D., & Spatz, I. (2021). Reining in pharmaceutical costs. USC White Paper.
Spatz, I. (2020). FDA calls states’ bluffs on drug importation. STAT, February 18, 2020.
Spatz, I., & Kolber, M. (2017). The future of essential health benefits. Health Affairs Blog.
Spatz, I. (2014). Medicare Part D proposed rule: Where did things go wrong. Health Affairs.
Spatz, I., McGee, N., Brennan, T., Berndt, E. R., & Lott, R. (2014). Specialty pharmaceuticals. Project HOPE.
Spatz, I. (February 9, 2011). Better Drug Ads, Fewer Side Effects. New York Times (Op-Ed).
Spatz, I. D. (2010). Health reform accelerates changes in the pharmaceutical industry. Health Affairs.
Berger, M., Honig, P., & Spatz, I. (2006). Comment: Medicare and cost-effectiveness analysis. New England Journal of Medicine, 354(2), 207-209.
McClellan, M., Spatz, I. D., & Carney, S. (2000). Designing A Medicare Prescription Drug Benefit: Issues, Obstacles, And Opportunities. Health Affairs, 19(2), 26-41.